Skip header and navigation

Refine By

18 records – page 1 of 2.

[Application of thrombolytic therapy of ischemic stroke in the Russian Federation].

https://arctichealth.org/en/permalink/ahliterature146385
Source
Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(12 Pt 2):17-22
Publication Type
Article
Date
2010
Author
V I Skvortsova
N A Shamalov
K V Anisimov
G R Ramazanov
Source
Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(12 Pt 2):17-22
Date
2010
Language
Russian
Publication Type
Article
Keywords
Aged
Female
Humans
Male
Middle Aged
Recombinant Proteins - adverse effects - therapeutic use
Russia - epidemiology
Stroke - drug therapy - mortality
Thrombolytic Therapy
Tissue Plasminogen Activator - adverse effects - therapeutic use
Treatment Outcome
Abstract
To study the efficacy and safety of thrombolytic therapy (TLT) with the recombinant tissue plasminogen activator (rt-PA) in stroke, we treated 691 patients in 48 clinical units using systemic or selective TLT. Safety and high efficacy of TLT was shown: the three-months fatality rate was 18.2%, the symptomatic hemorrhage transformation rate related to clinical worsening was 6.1%. The good functional recovery (scores 0 or 1 on the modified Rankin scale) was observed in 48.6% of patients.
PubMed ID
21630489 View in PubMed
Less detail

[Attempt to use the genetically engineered growth hormone SAIZEN in children with somatotropic insufficiency: results of clinical trials in Russia].

https://arctichealth.org/en/permalink/ahliterature217071
Source
Probl Endokrinol (Mosk). 1994 Nov-Dec;40(6):30-4
Publication Type
Article
Author
I I Dedov
V A Peterkova
N P Goncharov
T I Buraia
O V Fofanova
S S Pankova
A I Bukhman
Source
Probl Endokrinol (Mosk). 1994 Nov-Dec;40(6):30-4
Language
Russian
Publication Type
Article
Keywords
Child
Dwarfism - blood - drug therapy
Female
Growth Hormone - adverse effects - deficiency - therapeutic use
Human Growth Hormone
Humans
Male
Protein Engineering
Recombinant Proteins - adverse effects - therapeutic use
Russia
Abstract
The efficacy and safety of SAISEN, a recombinant human growth hormone obtained from mammalian cells, was tested in children with hypophyseal nanism. The treatment duration was 1 year. The results indicate that SAISEN (ARES-SERONO) is a highly effective and safe preparation of growth hormone, noticeably stimulating the growth rate both in previously untreated children with somatotropic insufficiency, and in those previously treated with STH preparations. Therapy with SAISEN was not associated with any side effects, as shown by both clinical and laboratory data.
PubMed ID
7740034 View in PubMed
Less detail

Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry.

https://arctichealth.org/en/permalink/ahliterature119003
Source
Circ Cardiovasc Interv. 2012 Dec;5(6):805-12
Publication Type
Article
Date
Dec-2012
Author
Benjamin Hibbert
Andrea MacDougall
Marino Labinaz
Edward R O'Brien
Derek Y F So
Alexander Dick
Christopher Glover
Michael Froeschl
Jean-Francois Marquis
George A Wells
Melissa Blondeau
Michel R Le May
Author Affiliation
Division of Cardiology, University of Ottawa Heart Institute, ON, Canada.
Source
Circ Cardiovasc Interv. 2012 Dec;5(6):805-12
Date
Dec-2012
Language
English
Publication Type
Article
Keywords
Aged
Anticoagulants - therapeutic use
Antithrombins - adverse effects - therapeutic use
Chi-Square Distribution
Drug Therapy, Combination
Female
Fibrinolytic Agents - adverse effects - therapeutic use
Hemorrhage - chemically induced - prevention & control
Heparin - therapeutic use
Hirudins - adverse effects
Hospital Mortality
Hospitals, University
Humans
Logistic Models
Male
Middle Aged
Myocardial Infarction - mortality - therapy
Odds Ratio
Ontario
Peptide Fragments - adverse effects - therapeutic use
Percutaneous Coronary Intervention - adverse effects - mortality
Platelet Aggregation Inhibitors - therapeutic use
Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors
Propensity Score
Recombinant Proteins - adverse effects - therapeutic use
Recurrence
Registries
Risk factors
Stroke - etiology - prevention & control
Thrombosis - etiology - prevention & control
Time Factors
Treatment Outcome
Abstract
Data from randomized trials has demonstrated the superiority of bivalirudin to glycoprotein IIb/IIIa inhibitors plus heparin in patients undergoing primary percutaneous coronary intervention. Real-world performance of bivalirudin in primary percutaneous coronary intervention and the benefit of bivalirudin over heparin remain unknown in an era of routine dual antiplatelet therapy.
From July 2004 to December 2010, 2317 consecutive patients were indexed in the University of Ottawa Heart Institute ST-segment-elevation myocardial infarction registry. During this period 748 patients received bivalirudin, 699 patients received glycoprotein IIb/IIIa inhibitors, and 676 patients received unfractionated heparin alone. The primary outcome was the rate of noncoronary artery bypass graft related thrombolysis in myocardial infarction major bleeding. Bivalirudin significantly reduced the primary outcome compared with heparin plus glycoprotein IIb/IIIa inhibitors (2.7% versus 7.3%, adjusted OR 2.96, 95% CI: 1.61-5.45, P
Notes
Comment In: Circ Cardiovasc Interv. 2013 Apr;6(2):e2623591425
Comment In: Circ Cardiovasc Interv. 2013 Apr;6(2):e2723591426
PubMed ID
23149331 View in PubMed
Less detail

Clinical safety surveillance study of the safety and efficacy of long-term home treatment with ReFacto utilizing a computer-aided diary: a Nordic multicentre study.

https://arctichealth.org/en/permalink/ahliterature92302
Source
Haemophilia. 2009 Jan;15(1):175-83
Publication Type
Article
Date
Jan-2009
Author
Petrini P.
Rylander C.
Author Affiliation
Department of Pediatrics, Coagulation Unit, Karolinska University Hospital, Stockholm, Sweden. pia.petrini@karolinska.se
Source
Haemophilia. 2009 Jan;15(1):175-83
Date
Jan-2009
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Child
Child, Preschool
Drug Administration Schedule
Factor VIII - adverse effects - therapeutic use
Hemophilia A - complications - drug therapy
Hemorrhage - etiology - prevention & control
Home Care Services, Hospital-Based
Humans
Infant
Male
Medical Records Systems, Computerized
Middle Aged
Product Surveillance, Postmarketing - methods
Recombinant Proteins - adverse effects - therapeutic use
Self Administration
Treatment Outcome
Young Adult
Abstract
A Nordic multicentre, open-label, non-interventional postmarketing surveillance study was carried out during a period of 24 months evaluating safety and efficacy of ReFacto as prophylactic or on-demand replacement therapy in patients with haemophilia A treated by self-medication. Fifty-seven patients were enrolled and studied for safety; efficacy was evaluated in 39 patients who received ReFacto for 24 months and recorded sufficient diary data on a hand-held computer. The compliance of using the device was good in small children, variable in adults and poor in teenagers. The fact that the overall compliance was low constituted a limitation of the number of patients with reliable diary data. Overall safety was rated as excellent or good by the clinicians for all patients at all visits and overall efficacy at 24 months evaluated to be excellent (74%) or good (26%). It was noticed that >/=50% of patients/parents reported no absences from school or work owing to bleeding episodes during the study period. Among patients on regular prophylaxis, 6 of the 30 patients (20%) receiving ReFacto experienced no bleeding episodes. A median of four bleeding episodes occurred during the 24-month study period, and 93% of the episodes were resolved with
PubMed ID
18752534 View in PubMed
Less detail
Source
Clin Perinatol. 2004 Mar;31(1):29-38
Publication Type
Article
Date
Mar-2004
Author
Robert D Christensen
Darlene A Calhoun
Author Affiliation
Department of Pediatrics, University of South Florida College of Medicine, 801 6th Avenue South, Box 9360, St. Petersburg, FL 33701, USA. rchriste@peds.ufl.edu
Source
Clin Perinatol. 2004 Mar;31(1):29-38
Date
Mar-2004
Language
English
Publication Type
Article
Keywords
Acids - urine
Antimicrobial Cationic Peptides - deficiency
Cardiomyopathy, Dilated - genetics
Cell Transformation, Neoplastic - chemically induced
Glycogen Storage Disease Type I - complications
Granulocyte Colony-Stimulating Factor - adverse effects - therapeutic use
History, 20th Century
Humans
Immune System Diseases - complications
Infant, Newborn
Leukocyte Elastase - genetics
Metabolism, Inborn Errors - complications
Mutation
Neutropenia - congenital - etiology - history - physiopathology
Proteins - genetics
Recombinant Proteins - adverse effects - therapeutic use
Sweden
Syndrome
Transcription Factors - genetics
Abstract
The term "congenital neutropenia" signifies neutropenia that is present at birth. It includes a wide variety of disorders, some transient and others life long. Some varieties of congenital neutropenia are mild, with blood neutrophil concentrations below normal but not low enough to constitute a significant host defense deficiency.Other varieties of congenital neutropenia are characterized by low blood neutrophil concentrations and a predisposition to repeated infections.
PubMed ID
15183654 View in PubMed
Less detail

Early drotrecogin alpha (activated) administration in severe sepsis is associated with lower mortality: a retrospective analysis of the Canadian ENHANCE cohort.

https://arctichealth.org/en/permalink/ahliterature150852
Source
Crit Care. 2009;13(3):R78
Publication Type
Article
Date
2009
Author
Richard V Hodder
Richard Hall
James A Russell
Harold N Fisher
Bobbie Lee
Author Affiliation
Division of Pulmonary and Critical Care Medicine, University of Ottawa, The Ottawa Hospital, Ottawa, ON, Canada. rhodder@ottawahospital.on.ca
Source
Crit Care. 2009;13(3):R78
Date
2009
Language
English
Publication Type
Article
Keywords
Aged
Anti-Infective Agents - adverse effects - therapeutic use
Biological Markers
Canada - epidemiology
Disease Progression
Female
Health Status Indicators
Humans
Logistic Models
Male
Middle Aged
Multivariate Analysis
Prognosis
Protein C - adverse effects - therapeutic use
Recombinant Proteins - adverse effects - therapeutic use
Retrospective Studies
Sepsis - diagnosis - drug therapy - mortality
Survival Analysis
Time Factors
Abstract
Early multimodal treatment of severe sepsis, including the use of drotrecogin alfa (activated) (DrotAA) when indicated, is considered essential for optimum outcome. However, predicting which infected patients will progress to severe sepsis and the need for aggressive intervention continues to be problematic. We therefore wished to explore whether there were any potential early markers that might predict improved survival in response to early use of DrotAA in patients with severe sepsis. In particular, in the dynamic setting of severe sepsis, we postulated that changes in markers reflecting evolving rather than baseline clinical status might guide therapy.
Data on a cohort of 305 Canadian patients from the open label ENHANCE trial of DrotAA in severe sepsis was retrospectively analyzed to search for potential clinical predictors of outcome in severe sepsis. Patients received a 96-hour infusion of DrotAA and were followed for 28 days. The association between time to treatment and mortality within subgroups defined by dynamic changes in various potential markers was explored.
Mortality at 28 days was 22.6% and the variables of age, time to treatment, and early changes in serum creatinine and platelet count were identified by logistic regression as independent predictors of mortality. Across all age ranges, 28-day mortality was lower when DrotAA was administered within 24 hours of first sepsis-induced organ dysfunction compared to administration after 24 hours for both subgroups of patients defined by changes in platelet count and creatinine within the first day.
These findings suggest that when indicated, treatment with DrotAA should be initiated as soon as possible, regardless of age.
Previous trial registration number: NCT00568893.
Notes
Cites: N Engl J Med. 2001 Mar 8;344(10):699-70911236773
Cites: Crit Care. 2007;11 Suppl 5:S318269690
Cites: Crit Care Med. 2001 Jul;29(7 Suppl):S109-1611445744
Cites: N Engl J Med. 2001 Nov 8;345(19):1368-7711794169
Cites: N Engl J Med. 2003 Apr 17;348(16):1546-5412700374
Cites: Am J Respir Crit Care Med. 2003 Jul 1;168(1):77-8412702548
Cites: Crit Care. 2003 Dec;7(6):445-5014624684
Cites: Crit Care Med. 2004 Sep;32(9):1825-3115343008
Cites: Chest. 1992 Jun;101(6):1644-551303622
Cites: Crit Care Med. 2005 Feb;33(2):341-815699837
Cites: Am J Respir Crit Care Med. 2005 Mar 1;171(5):461-815531752
Cites: Pharmacotherapy. 2005 Jan;25(1):26-3415767217
Cites: Acad Emerg Med. 2005 Apr;12(4):352-915805328
Cites: Med Decis Making. 2005 Jul-Aug;25(4):374-8616061889
Cites: Crit Care. 2005;9 Suppl 4:S20-616168070
Cites: Crit Care. 2005;9 Suppl 4:S38-4516168074
Cites: Crit Care Med. 2005 Oct;33(10):2194-20116215369
Cites: Crit Care Med. 2005 Oct;33(10):2266-7716215381
Cites: CMAJ. 2005 Oct 25;173(9):1054-6516247103
Cites: Crit Care. 2005;9(6):R764-7016356225
Cites: Crit Care Med. 2006 Jun;34(6):1589-9616625125
Cites: Crit Care. 2006;10(3):R7416684364
Cites: Ann Emerg Med. 2007 Jan;49(1):88-98, 98.e1-217095120
Cites: Crit Care. 2006;10(6):23917169139
Cites: Intensive Care Med. 2007 Mar;33(3):517-2317325837
Cites: Crit Care Med. 2007 May;35(5):1244-5017414736
Cites: Crit Care Med. 2008 Jan;36(1):296-32718158437
Cites: Crit Care Med. 2001 Jul;29(7 Suppl):S99-10611445742
PubMed ID
19457240 View in PubMed
Less detail

Experience of recombinant activated factor VII (NovoSeven) in the operating theatre and intensive care unit for the management of intracranial bleeding in nonhaemophilic patients.

https://arctichealth.org/en/permalink/ahliterature86277
Source
Clin Neurol Neurosurg. 2008 Mar;110(3):227-32
Publication Type
Article
Date
Mar-2008
Author
Felfernig Michael
Huepfl Michael
Author Affiliation
Department of Anaesthesia and General Intensive Care, Medical University Vienna, Waehringerguertel 18-20, 1090 Vienna, Austria. felfernigMD@doctors.org.uk
Source
Clin Neurol Neurosurg. 2008 Mar;110(3):227-32
Date
Mar-2008
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Anticoagulants - therapeutic use
Child
Child, Preschool
Databases, Factual
Factor VII - adverse effects - therapeutic use
Female
Humans
Infant
Intensive Care Units
Intracranial Hemorrhages - drug therapy - mortality - prevention & control
Intraoperative Complications - drug therapy - prevention & control
Male
Middle Aged
Neurosurgical Procedures
Postoperative Complications - drug therapy - mortality - prevention & control
Recombinant Proteins - adverse effects - therapeutic use
Retrospective Studies
Treatment Outcome
Abstract
OBJECTIVE: Intracranial haemorrhage (ICH) is associated with high morbidity and mortality. Our aim was to explore the use of recombinant activated factor VII (rFVIIa NovoSeven Novo Nordisk, A/S, Bagsvaerd, Denmark) for the management of ICH in the operating theater and intensive care unit. PATIENTS AND METHODS: We reviewed all the records of nonhaemophilic patients entered into the haemostasis.com database who received rFVIIa for ICH. RESULTS: Sixteen suitable patients were identified (mean age: 23.3 years; range: 1-58 years). The total dose of rFVIIa administered ranged from 31 to 270 microg/kg. Indications were stabilization of ICH (n=6), control of peri- or post-operative haemorrhage associated with neurosurgical procedures (n=8), or correction of coagulopathy prior to neurosurgical intervention (n=2). The majority (13/16 [81.25%]) required one dose of rFVIIa. A clinical effect (stabilization of bleed, reduction of peri- or post-operative haemorrhage, or prevention of excessive blood loss during neurosurgery) was seen in 14/16 (87.5%) patients. Some improvement in coagulation status was noted. No thromboembolic events were reported. One patient experienced massive elevation of D-dimer levels-an effect possibly due to rFVIIa. Two patients suffered adverse events unrelated to rFVIIa. Six deaths occurred, all attributable to underlying brain injury. CONCLUSION: This observational study suggests that rFVIIa is of value for the management of ICH in nonhaemophilic patients secondary to a range of aetiologies. These findings justify further investigation.
PubMed ID
18083302 View in PubMed
Less detail

Growth hormone treatment in adults with Prader-Willi syndrome: the Scandinavian study.

https://arctichealth.org/en/permalink/ahliterature129674
Source
Endocrine. 2012 Apr;41(2):191-9
Publication Type
Article
Date
Apr-2012
Author
Rasmus Sode-Carlsen
Stense Farholt
Kai Fr Rabben
Jens Bollerslev
Thomas Schreiner
Anne Grethe Jurik
Jens Sandahl Christiansen
Charlotte Höybye
Author Affiliation
Department of Paediatrics, Centre for Rare Diseases, Aarhus University Hospital Skejby, 8200 Aarhus N, Denmark.
Source
Endocrine. 2012 Apr;41(2):191-9
Date
Apr-2012
Language
English
Publication Type
Article
Keywords
Adult
Body Composition - drug effects
Cohort Studies
Diabetes Complications - blood - drug therapy - metabolism - physiopathology
Double-Blind Method
Female
Follow-Up Studies
Human Growth Hormone - adverse effects - therapeutic use
Humans
Insulin Resistance
Insulin-Like Growth Factor I - analysis
Male
Middle Aged
Peak Expiratory Flow Rate - drug effects
Prader-Willi Syndrome - blood - drug therapy - metabolism - physiopathology
Recombinant Proteins - adverse effects - therapeutic use
Scandinavia
Severity of Illness Index
Young Adult
Abstract
Prader-Willi syndrome (PWS) is characterized by short stature, muscular hypotonia, cognitive dysfunction, and hyperphagia usually leading to severe obesity. Patients with PWS share similarities with growth hormone deficiency (GHD). Few studies have dealt with growth hormone (GH) treatment in PWS adults. The purpose of the Scandinavian study was to evaluate the effects of GH on body composition, lipid and glucose metabolism, physical performance and safety parameters in adults with PWS. Twenty-five women and 21 men with PWS were randomized to treatment with GH or placebo during 1 year followed by 2 years of open labeled GH treatment. At baseline 1/3 had normal BMI, six patients severe GHD, ten impaired glucose tolerance and seven diabetes. At 1 year insulin-like growth factor I (IGF-I) SDS had increased by 1.51 (P 
PubMed ID
22081257 View in PubMed
Less detail

The impact of recombinant parathyroid hormone on malignancies and mortality: 7 years of experience based on nationwide Danish registers.

https://arctichealth.org/en/permalink/ahliterature263082
Source
Osteoporos Int. 2014 Feb;25(2):639-44
Publication Type
Article
Date
Feb-2014
Author
U C Bang
L. Hyldstrup
J E B Jensen
Source
Osteoporos Int. 2014 Feb;25(2):639-44
Date
Feb-2014
Language
English
Publication Type
Article
Keywords
Aged
Bone Density Conservation Agents - adverse effects - therapeutic use
Denmark - epidemiology
Female
Humans
Lung Neoplasms - chemically induced - mortality
Male
Middle Aged
Neoplasms - chemically induced - mortality
Osteoporosis - drug therapy - mortality
Parathyroid Hormone - adverse effects - therapeutic use
Recombinant Proteins - adverse effects - therapeutic use
Registries
Sex Factors
Abstract
We used Danish registers to identify patients with osteoporosis, who had been treated with parathyroid hormone and evaluated the probability of developing cancer. We did not find an increased risk of cancer among the patients treated with parathyroid hormone.
We evaluated the incidences of malignancies and mortality in osteoporotic patients treated with rPTH.
Using Danish nationwide registers, we identified patients diagnosed with osteoporosis in the period 1995 through 2010. Each patient treated with rPTH ("case") was compared with 10 gender- and age-matched patients who did also have osteoporosis but did not receive rPTH ("control").
A total of 4,104 cases (80.3 % females) were identified. The mean age at the beginning of rPTH treatment was 70.9 (SD 9.7) years. During a follow-up time of 10,118 person-years for the cases and 88,005 person-years for the controls, a total of 255 cases (6.2 %) compared with 2,103 controls (5.1 %) experienced a cancer (Chi square, p = 0.003). We found an adjusted cancer related HR of 1.1 (95 %CI 0.9-1.4) among the cases. Lung cancer was the only cancer type with a significantly increased rate among patients receiving rPTH (HR 1.7; 95 % CI 1.3-2.3). No cases developed osteosarcomas and nine controls developed osteosarcoma. During follow-up, 627 (15.3 %) cases died and 4,175 (10.2 %) controls died, which yielded an excess mortality risk of 26 % (95 % CI 16-37 %). This could be due to differences in the prevalence of vertebral fractures between the rPTH-treated and non-treated patients.
This study did not support the hypothesis describing a possible link between rPTH treatment and the development of cancer. We also conclude that osteosarcoma has not been diagnosed in any Danish patient receiving rPTH since the year 2003 when it was introduced on the market.
PubMed ID
23943162 View in PubMed
Less detail

18 records – page 1 of 2.